Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, Including ALS ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

Third Rock Ventures, the well-known backer of biotechnology companies, is leading a nine-figure fundraising round for a ...

Trace Neuroscience launched on Tuesday to announce that it is developing a genetic treatment targeting UNC13A, a gene linked ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Verve Therapeutics (VERV – Research Report) and decreased the ...

"UNC13A is a highly compelling genetic target directly linked to ALS disease progression and survival. Insights from the human genome have led to transformative medicines for many diseases, and with ...

There is only one eye bank based in Idaho. Envision Eye Bank in Boise helped with around 200 eye transplants in 2023.

In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory ... we are ...

Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

The payload consists of modular oligonucleotides to target genetic mutations that produce the muscle condition ... Likewise, ...